26th February 2015
Glyconics Appoints Jeremy Williams as Non-Executive Director
Glyconics Limited has appointed Jeremy Williams as non-executive director, joining the Board of Directors. Glyconics, an innovative UK diagnostics company, is a spinout from Swansea University and is developing a novel diagnostic technology for the management of Chronic Obstructive Pulmonary Disease (COPD).
Jeremy joins the fast-growing company as it gears up for full commercialisation of its first product having secured a Small Business Research Initiative (SBRI) contract from NHS England to assess the clinical performance of the technology.
Jeremy brings considerable experience to the Board having been an entrepreneur and medical communications professional for many years. He is currently non-executive Chairman of Assembly Studios, in London and Abu Dhabi, Associate Director at SI Partners Global, a London-based firm offering management consultancy and corporate finance advice across Europe, Asia and North America. Jeremy is also founder of Stratus Communications Ltd, helping
businesses to improve their performance, to manage rapid growth and to develop an exit strategy.
Prior to this, Jeremy was CEO and owner of ScopeMedical Ltd, a medical communications provider with clients from the global pharmaceutical industry, creating and implementing global healthcare communication programs. The company was the fastest growing firm in its sector had offices in the UK and US. Having led an MBO and subsequent business turnaround, Jeremy steered the company to seven fold growth over the next seven years. When he took the businesses to market they were acquired by Huntsworth Plc in an £11m acquisition in 2010.
Dr Berwyn Clarke, CEO of Glyconics, said: “Jeremy joins Glyconics at an exciting time in the Company’s development as we build the Board and corporate infrastructure which will support the rapid progression of the technology. Jeremy brings great experience from the fields of medical education and medical communications, which will be valuable to Glyconics. Not only that, but he is an experienced non-executive director and we look forward to working closely with him at this exciting stage of the Company’s development.”
Jeremy Williams, non-executive director of Glyconics, added: “I am delighted to join the board of Glyconics. The company has an excellent technology, which meets a significant unmet clinical need, and I believe that this will be a highly significant commercial opportunity.”
For further information, contact:
Tony Stephenson
Exitus Communications
+44 (0)7899 796655 tony@exituscommunications.co.uk
About Glyconics:
Glyconics is an innovative diagnostics company, which is developing novel diagnostics for respiratory disease including COPD. Using Infrared Spectroscopy, Glyconics has developed a solution to the current problems in diagnosing COPD, identifying its severity, and monitoring disease progression including early indication of exacerbation. Currently there is no effective diagnosis for COPD, and by meeting this unmet clinical need, Glyconics is well placed to take advantage of a major unmet global market opportunity. As well as COPD Glyconics is developing a pipeline of biomarker signatures for other respiratory diseases as well as potential oncology indications.